ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor ModelsCherrie K. Donawho, David J. Frost, Yan Luo et al.|Clinical Cancer Research|2007Cited by 770
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trialsGregory J. Dore, Thomas Podsadecki, Brygida Knysz et al.|Journal of Hepatology|2015Cited by 68